San Antonio Breast Cancer Symposium 2019
Masakazu Toi (Kyoto University Hospital, Kyoto, Japan) presented the results of the randomised, phase 3 POTENT trial. 1959 patients with hormone receptor-positive, HER2-negative, stage I–III primary breast cancer at intermediate or high risk of recurrence were randomly assigned (1:1) after surgery to standard adjuvant endocrine therapy alone (control) or with oral S-1 (80 mg, 100 mg, or 120 mg…